Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01155284 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
A Phase 2 study, sponsored by Sanford Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01155284 is a Phase 2 study that has completed, run by Sanford Health. The registered enrollment target is 70 participants.
The verdict
NCT01155284, a Phase 2 study, has completed, sponsored by Sanford Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
Sanford Research/USD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset diabetes and possibly regenerating their beta cells, while safely down-regulating the autoimmune response directed against the beta cells.
Interventions
- DRUG Placebo
- DRUG Sitagliptin and Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01155284
The ClinicalTrials.gov registry entry for NCT01155284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanford Health, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01155284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01155284 about?
NCT01155284 is a clinical study titled "Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes". Sanford Research/USD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset diabetes and possibly regenerating their beta cells, while safely down-regula...
What is the current status of trial NCT01155284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2010-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01155284?
The interventions under investigation include: Placebo (DRUG), Sitagliptin and Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT01155284?
This trial is sponsored by Sanford Health, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.